Blueprint Medicines Corporation - Common Stock (BPMC)
87.11
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 4th, 6:22 AM EDT
Detailed Quote
Previous Close
87.11
Open
-
Bid
34.85
Ask
139.37
Day's Range
N/A - N/A
52 Week Range
80.68 - 121.90
Volume
389
Market Cap
5.53B
PE Ratio (TTM)
-79.92
EPS (TTM)
-1.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,037,997
Chart
About Blueprint Medicines Corporation - Common Stock (BPMC)
Blueprint Medicines Corporation is a biotechnology company that focuses on developing targeted therapies for patients with genomically defined cancers, rare diseases, and cancer-related conditions. The company's innovative approach centers around understanding specific genetic mutations that drive diseases, allowing them to design and produce precision medicines that can more effectively address the underlying causes of these conditions. With a commitment to advancing cancer treatment, Blueprint Medicines aims to improve patient outcomes by delivering personalized therapies based on individual genetic profiles. Read More
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
LOS ANGELES, May 26, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Blueprint Medicines Corporation (“Blueprint” or “the Company”) (NASDAQ: BPMC) for potential breaches of fiduciary duty on the part of its directors and management.
